Aquestive Therapeutics, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Aquestive adopted amended and restated bylaws effective October 15, 2024, revising stockholder nomination and meeting procedures. Changes include updated timing windows for stockholder nominations (90–120 days before annual meetings), enhanced disclosure requirements for nominee candidates and nominating stockholders, implementation of Rule 14a-19 compliance provisions, restrictions on non-white proxy card use by stockholders, and clarified procedures for special meetings. No counterparties, dollar amounts, or share counts involved.
Why this rating
Routine corporate governance update; bylaw amendments are standard administrative housekeeping with no direct business or financial impact. No material economic consequences for a $291.6M company.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.